Elanco Animal Health Incorporated (ELAN) |
|
12.15 -0.42 (-3.34%)
|
11-28 16:00 |
|
Open: |
12.4 |
Pre. Close: |
12.57 |
|
High:
|
12.59 |
Low:
|
12.1 |
|
Volume:
|
4,965,565 |
Market Cap:
|
5,762(M) |
|
|
|
Technical analysis |
as of: 2022-11-28 4:39:25 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 15.21  One year: 16.16 |
| Support: |
Support1: 11.71 Support2: 9.74 |
| Resistance: |
Resistance1: 13.02 Resistance2: 13.84 |
| Pivot: |
12.5 |
| Moving Average: |
MA(5): 12.29 MA(20): 12.65
MA(100): 15.37 MA(250): 21.38 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 27.9 %D(3): 28.4 |
| RSI: |
RSI(14): 44.8 |
| 52-week: |
High: 29.76 Low: 11.34 |
| Average Vol(K): |
3-Month: 7,509 (K) 10-Days: 6,216 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ELAN ] has closed above bottom band by 32.6%. Bollinger Bands are 20% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
12.61 - 12.67 |
12.67 - 12.72 |
|
Low:
|
11.96 - 12.03 |
12.03 - 12.08 |
|
Close:
|
12.05 - 12.16 |
12.16 - 12.24 |
|
Company Description |
|
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana. |
Headline News |
Mon, 28 Nov 2022
Trump’s former antisemitism envoy calls Trump out for meeting with Kanye West and Nick Fuentes - JTA News - Jewish Telegraphic Agency
Mon, 28 Nov 2022
Elan 2023 Ripstick Tour Review: An All-Mountain Go-To Setup for Backcountry Touring - GearJunkie
Mon, 28 Nov 2022
What do the Fundamentals Predict for Elanco Animal Health Inc (ELAN) Stock? - InvestorsObserver
Fri, 25 Nov 2022
ISPO Award Winner 2022: Elan Primetime 55 Ski - ISPO
Tue, 22 Nov 2022
How Thanksgiving Became Turkey Day, According to Animal Studies Professor Elan Abrell - Wesleyan University
Sat, 19 Nov 2022
Here's Why The Lotus Elan M100 Is A Gravely Underrated Sportscar - HotCars
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
474 (M) |
| Shares Float |
444 (M) |
|
% Held by Insiders
|
0.2 (%) |
|
% Held by Institutions
|
98.3 (%) |
|
Shares Short
|
12,410 (K) |
|
Shares Short P.Month
|
11,170 (K) |
Stock Financials |
|
EPS
|
-0.75 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
14.22 |
|
Profit Margin (%)
|
-2.7 |
|
Operating Margin (%)
|
10.4 |
|
Return on Assets (ttm)
|
1.8 |
|
Return on Equity (ttm)
|
-1.7 |
|
Qtrly Rev. Growth
|
-9.2 |
|
Gross Profit (p.s.)
|
5.67 |
|
Sales Per Share
|
9.57 |
|
EBITDA (p.s.)
|
2.34 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
662 (M) |
|
Levered Free Cash Flow
|
639 (M) |
Stock Valuations |
|
PE Ratio
|
-16.2 |
|
PEG Ratio
|
1.2 |
|
Price to Book value
|
0.85 |
|
Price to Sales
|
1.26 |
|
Price to Cash Flow
|
8.7 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
